Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLELE phase 3 study of Ebvallo in EBV-positive post-transplant lymphoproliferative disease after rituximab failure
2024-516622-57-00Phase 3Authorised
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2020
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 3, open-label trial of tabelecleucel in Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) (2 cohorts), sponsored by Pierre Fabre Laboratories. Primary endpoint: Overall response rate. Planned start May 2020; status: authorised.
02
Drugs
tabelecleucel
03
Conditions
Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD)
Beyond the preview
Go deeper on 2024-516622-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516622-57-00.